Abstract
The novel coronavirus (2019-nCoV) is an emerging causative agent that was first described in late December 2019 and causes a severe respiratory infection in humans. Notably, many of affected patients of COVID-19 were people with malignancies. Moreover, cancer has been identified as an individual risk factor for COVID-19. In addition, the expression of angiotensin converting enzyme 2 (ACE2), the receptor of COVID-19, were aberrantly expressed in many tumors. However, a systematic analysis of ACE2 aberration remained to be elucidated in human cancers. Here, we analyzed genetic alteration, RNA expression, and DNA methylation of ACE2 across over 30 tumors. Notably, overexpression of ACE2 have been observed in including colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and lung adenocarcinoma (LUAD). In addition, hypo DNA methylation of ACE2 has also been identified in most of these ACE2 highly expressed tumors. Conclusively, our study for the first time curated both genetic and epigenetic variations of ACE2 in human malignancies. Notably, because our study is a bioinformatics assay, further functional and clinical validation is warranted.
Keywords: COVID-19, ACE2, Expression
To the editor,
The novel Coronavirus disease 2019 (COVID-19) is the causative agent of a severe respiratory infection, which is of global public health concern [1, 2]. To date (17 April 2020), COVID-19 has resulted in a total of 2,175,460 laboratory-confirmed human infections, including 146,536 deaths. Moreover, cancer has been already identified as an individual risk factor for COVID-19 [3, 4]. However, a systematic analysis of ACE2 aberration remained uncharacterized in human cancers.
We then curated a pan-cancer analysis of ACE2 in malignancies. In TCGA pan-cancer panel, the most frequent DNA alteration is mutation. Mutations were mainly distributed in UCEC, SKCM, UCS and STAD (Figure S1A). In another pan-cancer panel, the most frequent DNA alteration is amplification. Amplifications of ACE2 were observed in NEPC and PRAD patients (Figure S1B). In addition, ACE2 mutations in malignancies were distributed across all exons of ACE2 without hot spot mutation site (Figure S2AC, Table S1). The most frequent mutation was H195Y/X195_splice (Figure S2B) and X555_splice (Figure S2D). Two most frequent mutations were distributed in the peptidase domain of ACE2, which were predicted to be inactivating mutations.
We next compared ACE2 expression in tumor and its normal control tissue. ACE2 expression was upregulated in six tumors while downregulated in three tumors (Table S2, Fig. 1a). Notably, COAD, KIRP, PAAD, READ, STAD and LUAD presented with increased ACE2 expression (Fig. 1b). Notably, because COVID-19 was mainly transmitted through air-way, we focus on respiratory system tumors. ACE2 was significantly upregulated in LUAD while remained unchanged in lung squamous cell carcinoma (Figure S3). Three tumors, including TGCT, THCA, and KICH, presented with decreased ACE2 expression (Fig. 1c). We then confirmed the relevance of genetic disorders and ACE2 expression. We found that mutations were not relevant to RNA expression (Figure S4A). In addition, we found DNA copy variation were neither statistically relevant to ACE2 expression (Figure S4B). Thus, it is possible that the upregulation of ACE2 expression was not resulted from genetic variation. We then examined the epigenetic disorders of ACE2 in cancers.
Four probes in ACE2 promoter were used for detecting DNA methylation level of ACE2 (Fig. 2a). We have found that the five highly ACE2 express tumors presented with decreased DNA methylation level of ACE2, including COAD, KIRP, PAAD, READ, and LUAD (Fig. 2b). Accordingly, an ACE2 downregulated tumor, TGCT, presented increased DNA methylation level (Fig. 2c). Since there is no available DNA methylation dataset for normal control of KICH, we could not compare global DNA methylation level of KICH. Instead, we compared DNA methylation level of KICH across different tumor stages, and we found that the DNA methylation was not significantly changed (Figure S5). In addition, DNA methylation level of ACE2 in THCA and STAD remained unchanged (Figure S6AB), which suggested DNA methylation might be not the only reason of abnormal ACE2 expression. Other possibilities, such as histone modifications [5] and glycosylation [6] may give rise in the abnormal expression of ACE2, which requires further explorations.
We then explored the impact of ACE2 expression in overall survival (OS) and disease-free survival (DFS). Six tumors (COAD, KIRP, PAAD, READ, STAD, and LUAD) presented with elevated ACE2 expression while three other tumors (TGCT, THCA, KICH) presented with decreased ACE2 expression; however, ACE2 expression was not statistically relevant to patients’ prognosis, neither in DFS (Figure S7) nor OS (Figure S8). For DFS, higher ACE2 expression predicted better outcome in KIRC, LIHC, LUSC, UCS, and OV groups (Figure S9A). For overall survival, higher ACE2 expression indicated better prognosis in KIRC, LIHC, and OV groups. However, higher ACE2 expression in LGG refers to unfavorable outcome, which indicated the ACE2 might function as a dual-edged sword for patients’ outcome (Figure S9B). Notably, ACE2 has been proven to be an important regulator in tumorigenesis. For instance, ACE2 inhibits breast cancer angiogenesis through suppressing VEGFa/VEGFR2/ERK pathway [7] and reduces cell invasion and migration in NSCLC cells [8].
Among these COVIDs with malignancies, LUAD was the most frequent type [3]. Moreover, patients with lung cancer were confirmed to harbor a higher incidence of COVID-19, with severer symptoms [3, 4]. Here, we have also proved that the ACE2 RNA expression was upregulated in LUADs. Since our study is only a database analysis, further validation in larger clinical cohort is warranted.
Supplementary information
Acknowledgements
Not applicable
Abbreviations
- COVID-19
Novel coronavirus disease 2019
- ACE2
Angiotensin converting enzyme 2
- TCGA
The cancer genome atlas
- UCEC
Uterine corpus endometrial carcinoma
- SKCM
Skin cutaneous melanoma
- THCA
Thyroid carcinoma
- COAD
Colon adenocarcinoma
- KIRP
Kidney renal papillary cell carcinoma
- PAAD
Pancreatic adenocarcinoma
- READ
Rectum adenocarcinoma
- STAD
Stomach adenocarcinoma
- NEPC
Neuroendocrine prostate cancers
- UCS
Uterine carcinosarcoma
- PRAD
Prostate adenocarcinoma
- KIRC
Kidney renal clear cell carcinoma
- KIRP
Kidney renal papillary cell carcinoma
- KICH
Kidney chromophobe
- LIHC
Liver hepatocellular carcinoma
- LUSC
Lung squamous cell carcinoma
- OV
Ovarian serous cystadenocarcinoma
- LUAD
Lung adenocarcinoma
- NSCLC
Non-small cell lung cancer
- OS
Overall survival
- DFS
Disease-free survival
- LGG
Brain lower-grade glioma
Authors’ contributions
In this report, PWC and JY designed and performed the experiments and drafted the manuscript; PWC and XQF were responsible for the sample collection and data analysis; SFG, RBJ and XQF discussed, revised and approved the manuscript. All the authors approved this manuscript.
Funding
This work was supported by the National Natural Science Foundation of China (81772875, 81770961, and U1932135), and the Science and Technology Commission of Shanghai (17DZ2260100 and 19JC1410200).
Availability of data and materials
Patients data were acquired from cBioportal (https://www.cbioportal.org/), UALCAN (http://ualcan.path.uab.edu/), and gepia2 (http://gepia2.cancer-pku.cn) database tool. We have referred DNA alterations, expression profiling, DNA methylation level of ACE2 promoter, mutation analysis, and Kaplan merrier analysis section (Table S3).
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Shengfang Ge, Email: geshengfang@sjtu.edu.cn.
Renbing Jia, Email: renbingjia@sjtu.edu.cn.
Xianqun Fan, Email: fanxq@sjtu.edu.cn.
Supplementary information
Supplementary information accompanies this paper at 10.1186/s13045-020-00883-5.
References
- 1.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Boldog P, Tekeli T, Vizi Z, Dénes A, Bartha FA, Röst G. Risk assessment of novel coronavirus COVID-19 outbreaks outside China. J Clin Med. 2020;9:571. 10.3390/jcm9020571. [DOI] [PMC free article] [PubMed]
- 3.Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi: 10.1016/S1470-2045(20)30096-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan. JAMA Oncol: China; 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V, Srinivasan K. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol. 2015;93:343–351. doi: 10.1016/j.bcp.2014.11.013. [DOI] [PubMed] [Google Scholar]
- 6.Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem. 2004;279:17996–18007. doi: 10.1074/jbc.M311191200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H, Qian X, Bi J, Lin Y. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019;38:173. doi: 10.1186/s13046-019-1156-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Xu J, Fan J, Wu F, Huang Q, Guo M, Lv Z, Han J, Duan L, Hu G, Chen L, et al. The ACE2/angiotensin-(1-7)/Mas receptor axis: pleiotropic roles in cancer. Front Physiol. 2017;8:276. doi: 10.3389/fphys.2017.00276. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Patients data were acquired from cBioportal (https://www.cbioportal.org/), UALCAN (http://ualcan.path.uab.edu/), and gepia2 (http://gepia2.cancer-pku.cn) database tool. We have referred DNA alterations, expression profiling, DNA methylation level of ACE2 promoter, mutation analysis, and Kaplan merrier analysis section (Table S3).